Exceptional Response of Necrolytic Migratory Erythema to Octreotide in a Patient with Glucagonoma: A Case Report and Scoping Review
Case Reports in Dermatology · 16.05.2026 · 18 (1) · 411-425
DOI: 10.1159/000552556 ↗Kurz gefasst
Fallbericht in der Zeitschrift Case Reports in Dermatology, online erschienen am 16.05.2026. Verfasst von Gabriela Rozo-Paz und 3 weiteren Autor:innen. Beteiligte Einrichtung: Facultad de Medicina, Universidad de Los Andes, Bogotá, Colombia. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Glucagonomas are rare neuroendocrine neoplasms (NENs) that often present with locoregional involvement at diagnosis and are characterized by variable survival outcomes and diverse therapeutic approaches. We present a clinical case of glucagonoma associated with necrolytic migratory erythema (NME), demonstrating an exceptional response to octreotide. Additionally, a scoping review was conducted to evaluate the efficacy of somatostatin analogs (SSAs) in managing NME.
Methods
Through a meticulous search on MEDLINE, we unearthed a collection of case reports and series that shed light on patients with glucagonoma and neuroendocrine tumors (NETs) who received treatment with somatostatin analogs (SSAs). A thorough extraction and analysis of pertinent data was conducted to deepen our understanding of these cases. Case Presentation: A 66-year-old woman consulted with a 4-year history of migratory, pruritic, and painful vesiculobullous skin lesions consistent with NME. Laboratory tests revealed serum glucagon levels exceeding 500 pg/mL, and magnetic resonance imaging identified a pancreatic mass with hepatic metastases. Octreotide therapy resulted in the complete resolution of cutaneous lesions within 4 days of the first dose. She chose not to undergo surgery or other treatment options, and as a result, she passed away due to the progression of her disease.
Results
Out of a total of 1,712 reviewed cases, 25 met the inclusion criteria. Among these cases, 56% of the patients were female, and the mean age at diagnosis was 59.74 years. Clinical improvement in NME was observed in 80% of patients treated with SSAs, with an average time to resolution of dermatological symptoms being 1.41 months. The median overall survival for these patients was 11 months.
Conclusion
Although SSAs demonstrated notable efficacy in the resolution of NME, their impact on overall survival remains limited. These results emphasize the importance of ongoing research and innovation in treating NENs to improve long-term patient outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Facultad de Medicina, Universidad de Los Andes, Bogotá, Colombia.
- Departamento de Medicina Interna, Oncología Endocrina, Instituto de Cáncer Carlos Ardila Lülle, Fundación Santa Fe de Bogotá, Bogotá, Colombia.
- Departamento de Radiología, Fundación Santa Fe de Bogotá, Bogotá, Colombia.
- Departamento de Medicina Interna, Dermatología, Fundación Santa Fe de Bogotá, Bogotá, Colombia.
Zitieren
APA
Rozo-Paz, G., González-Devia, D., Aguirre-Matallana, D. A., & Chalela-Mantilla, J. G. (2026). Exceptional Response of Necrolytic Migratory Erythema to Octreotide in a Patient with Glucagonoma: A Case Report and Scoping Review. Case Reports in Dermatology, 18(1), 411-425. https://doi.org/10.1159/000552556
Vancouver
Rozo-Paz G, González-Devia D, Aguirre-Matallana DA, Chalela-Mantilla JG. Exceptional Response of Necrolytic Migratory Erythema to Octreotide in a Patient with Glucagonoma: A Case Report and Scoping Review. Case Reports in Dermatology. 2026;18(1):411-425. doi:10.1159/000552556
BibTeX
@article{RozoPaz2026,
author = {Rozo-Paz, Gabriela and González-Devia, Deyanira and Aguirre-Matallana, Diego Andres and Chalela-Mantilla, Juan Guillermo},
title = {Exceptional Response of Necrolytic Migratory Erythema to Octreotide in a Patient with Glucagonoma: A Case Report and Scoping Review},
journal = {Case Reports in Dermatology},
year = {2026},
volume = {18},
number = {1},
pages = {411--425},
doi = {10.1159/000552556}
}
EUVIMED